<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:mp ids='MP_0002959'>Microalbuminuria</z:mp> independently predicts the development of <z:hpo ids='HP_0000112'>nephropathy</z:hpo> and increased <z:e sem="disease" ids="C1301700" disease_type="Disease or Syndrome" abbrv="">cardiovascular morbidity</z:e> and mortality in diabetic patients, but it may be an indicator of the <z:hpo ids='HP_0011009'>acute</z:hpo> phase response </plain></SENT>
<SENT sid="1" pm="."><plain>This study examined <z:mp ids='MP_0002959'>microalbuminuria</z:mp> as a marker of the <z:hpo ids='HP_0011009'>acute</z:hpo> phase response in patients with <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel disease</z:e> and correlated it with the disease activity in 95 patients with <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel disease</z:e> (<z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo> (n = 52), <z:hpo ids='HP_0100280'>Crohn's disease</z:hpo> (n = 43)) determined by the simple index of Harvey and Bradshaw </plain></SENT>
<SENT sid="2" pm="."><plain>Fifty patients were in complete clinical remission and 45 patients had active disease </plain></SENT>
<SENT sid="3" pm="."><plain><z:mp ids='MP_0002959'>Microalbuminuria</z:mp> was detected in <z:hpo ids='HP_0000001'>all</z:hpo> patients with <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel disease</z:e> (147 (17) v 18 (2) microgram/min, <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel disease</z:e> v controls mean (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SEM</z:e>), p &lt; 0.007) </plain></SENT>
<SENT sid="4" pm="."><plain>Patients with active <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel disease</z:e> had higher concentrations of <z:mp ids='MP_0002959'>microalbuminuria</z:mp> compared with patients in remission (206 (19) v 65 (8) microgram/min, mean (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SEM</z:e>), p &lt; 0.0001) </plain></SENT>
<SENT sid="5" pm="."><plain>Eight patients with active <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel disease</z:e> who were sequentially followed up with measurements of <z:mp ids='MP_0002959'>microalbuminuria</z:mp> had significantly lower values, when the disease was inactive (active <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel disease</z:e> 192 (44) v inactive <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel disease</z:e> 64 (14) microgram/min, p &lt; 0.03) </plain></SENT>
<SENT sid="6" pm="."><plain>There was a significant correlation with the simple index of Harvey and Bradshaw (r = 0.818, p &lt; 0.0001) </plain></SENT>
<SENT sid="7" pm="."><plain><z:mp ids='MP_0002959'>Microalbuminuria</z:mp> values were significantly lower in <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel disease</z:e> patients in remission, maintained with olsalazine compared with those patients maintained with <z:chebi fb="0" ids="6775">mesalazine</z:chebi> and salazopyrine, but no significant difference was seen in values of <z:mp ids='MP_0002959'>microalbuminuria</z:mp> in active <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel disease</z:e> patients receiving different <z:chebi fb="1" ids="30762">salicylates</z:chebi> </plain></SENT>
<SENT sid="8" pm="."><plain>This study also measured serum amyloid-A as an indicator of the <z:hpo ids='HP_0011009'>acute</z:hpo> phase response in the same patients </plain></SENT>
<SENT sid="9" pm="."><plain>Serum amyloid-A was significantly increased in active disease compared with inactive disease (151 (43) v 33 (7) or controls 11 (2) micrograms/ml, p &lt; 0.05) </plain></SENT>
<SENT sid="10" pm="."><plain>In conclusion <z:mp ids='MP_0002959'>microalbuminuria</z:mp> is present in abnormal amounts in <z:hpo ids='HP_0000001'>all</z:hpo> patients with active <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel disease</z:e>, and values fall when the disease is quiescent </plain></SENT>
<SENT sid="11" pm="."><plain><z:mp ids='MP_0002959'>Microalbuminuria</z:mp> is probably a consequence of an <z:hpo ids='HP_0011009'>acute</z:hpo> phase response and provides a simple, rapid, and inexpensive test, which has the potential to monitor <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel disease</z:e> activity and response to treatment </plain></SENT>
</text></document>